▲ Peaking
Business
Novo Nordisk raises 2026 outlook as Q3 obesity sales jump 22%
3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Novo Nordisk
35 trends tracked about this subject — the full history, oldest to newest below.
▲ Peaking
Business
Novo Nordisk Lifts Guidance as Rollout of Wegovy Weight-Loss Pill Continues
13 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
US judge refuses to block Eli Lilly weight-loss drug ads, rules against Novo Nordisk
A US judge has ruled against Novo Nordisk, allowing Eli Lilly to continue running advertisements for its weight-loss medications.
◼ Archived
Business
Novo's next-generation obesity drug shows 25% weight loss in women in late-stage analysis
Novo's next-generation obesity drug CagriSema showed 25 percent weight loss in women in late-stage analysis.
◼ Archived
Health
Novo Nordisk and Eli Lilly Just Got Some Fantastic News
Novo Nordisk and Eli Lilly receive positive news amid ongoing developments in drug discovery and aging research.
◼ Archived
Health
GLP-1 weight-loss drugs slow biological aging, recent studies show
Recent studies indicate that popular GLP-1 weight-loss medications like Ozempic and Mounjaro may also slow biological aging.
◼ Archived
Business
‘Triple-G’ weight loss drug update: Even on the lowest dose, trial patients lost 12.7% of their weight
3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
The Next Frontier for Obesity Drugs Isn’t How Much Weight You Lose, but What Kind
9 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
People switching to Novo's Wegovy pill from obesity injections kept losing weight in real-world study
Real-world study data reveals patients switching from obesity injections to Novo Nordisk's oral Wegovy pill continue to lose weight.
◼ Archived
Health
Once described as obesity medicines for 'patients,' GLP-1s are increasingly lifestyle drugs for 'customers'
GLP-1 medications are shifting from clinical obesity treatments for patients to lifestyle products for customers, amid a surge in oral pill options.
◼ Archived
Business
Novo Nordisk to Pay Up to $1.3 Billion for Nanexa’s Drug Delivery Technology
Novo Nordisk strikes a $1.3 billion deal with Nanexa to secure long-acting obesity injection technology.
◼ Archived
Business
Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s
Novo Nordisk unveils its next growth engine at Capital Markets Day as competitor Eli Lilly gains ground in GLP-1s.
◼ Archived
Business
GLP-1 makers Novo, Eli Lilly sued over sudden loss of vision in patients
Major drugmakers Novo Nordisk and Eli Lilly face numerous lawsuits alleging popular GLP-1 medications cause sudden vision loss.
◼ Archived
Business
Novo struggles to appease restive investors with consumer plans, blockbuster ambitions
4 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
Wegovy-maker Novo faces calls to map out strategy beyond weight-loss drugs
Novo Nordisk shares slide despite aggressive obesity targets as investors demand a broader long-term strategy.
◼ Archived
Health
Novo Nordisk (NVO) and Eli Lilly (LLY)’s Weight-Loss Drugs Still Work at Smaller Doses, Study Finds
Recent studies indicate that popular weight-loss treatments manufactured by Novo Nordisk and Eli Lilly retain efficacy at reduced doses.
◼ Archived
Business
Novo explores macrocycles’ potential in $1.4B cardiometabolic pact with Danish biotech
Novo Nordisk signs a licensing agreement worth up to $1.4 billion with Orbis Medicines to develop oral therapeutics.
◼ Archived
Business
Novo Nordisk rebrands to 'Novo,' unveils corporate changes as it fights for obesity market share
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
🔮 fades ✓
A Promising Heart Drug Failed. What Went So Wrong?
The failure of heart drug trials from pharmaceutical giants Novartis and Novo Nordisk creates a significant setback for a promising field of medicine.
◼ Archived
Business
🔮 fades ✓
Novo’s blockbuster hopes for CKD program dwindle after more phase 3 trials scrapped
Novo Nordisk faces a divergent clinical outlook as its pediatric obesity trials succeed while heart drug programs for CKD suffer setbacks.
◼ Archived
Business
🔮 fades ✗
Novo Nordisk stops two cardiovascular trials of drug aimed at lowering inflammation
Novo Nordisk has halted two clinical trials for Ziltivekimab, an experimental cardiovascular drug designed to reduce inflammation.
◼ Archived
Business
🔮 fades ✗
Novo Nordisk Says Wegovy Shot Helped Children Lose Weight in Trial
Novo Nordisk's Wegovy shows weight-loss results in young children during trial data releases.
◼ Archived
Business
🔮 fades ✗
Novo scraps two more heart drug trials, further dimming growth beyond obesity
Novo Nordisk faces a diverging trajectory as it meets pediatric obesity goals but terminates two heart disease drug trials.
◼ Archived
Business
🔮 fades ✓
Updated: Novo Nordisk cans 2 more trials of IL-6 heart drug for futility
Novo Nordisk has terminated two additional phase 3 trials of its cardiovascular drug ziltivekimab due to futility, impacting its growth strategy.
◼ Archived
Business
🔮 fades ✗
How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy?
Novo Nordisk’s once‑dominant GLP‑1 weight‑loss line now faces a fierce showdown with Eli Lilly, sparking questions about Europe’s biotech edge.
◼ Archived
Business
🔮 fades ✓
Novo outlook hike falls flat as Wegovy pill sales fail to impress
4 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
🔮 fades ✓
Novo Nordisk shares slide after guidance disappoints investors
Novo Nordisk shares decline despite Q2 profit beats and raised forecasts, amid intensifying competition with Eli Lilly.
◼ Archived
Business
🔮 fades ✓
Novo Nordisk rocked by late-stage cardiovascular drug failure
Pharmaceutical giant Novo Nordisk faces a significant setback following the failure of a late-stage cardiovascular drug trial.
◼ Archived
Business
🔮 fades ✓
Novo drug trial fail deals setback to bid to expand beyond obesity
Novo Nordisk faces a significant setback in expanding beyond obesity as a key phase 3 trial delivers disappointing results.
◼ Archived
Business
🔮 holds
Novo sues Lilly, claiming misleading ads in weight-loss drug battle
Novo Nordisk has filed a lawsuit against Eli Lilly over allegations of deceptive and misleading advertising regarding GLP-1 weight-loss drugs.
◼ Archived
Business
🔮 fades
Novo Nordisk sues Eli Lilly, alleging misleading GLP-1 advertising
Novo Nordisk has launched a legal offensive against Eli Lilly, alleging that the competitor's GLP-1 weight-loss drug advertising is deceptive.
◼ Archived
Health
🔮 fades
The Next Wave Of Peptides Could Be Here; What Does It Mean For Lilly, Novo?
FDA’s new peptide panel sparks regulatory debate as biotech giants Lilly and Novo eye the next health wave.
◼ Archived
Business
🔮 fades
A tiny GLP-1 implant is the latest bet to help patients maintain their weight loss
Novo Nordisk and Vivani are partnering to develop a long-acting semaglutide implant designed to improve weight loss adherence for up to a year.
◼ Archived
Business
🔮 fades
Medicare is now offering $50 GLP-1 prescriptions. The US may never be the same.
Medicare has introduced $50 prescriptions for GLP-1 medications, signaling a potential shift in the US healthcare and pharmaceutical landscape.
◼ Archived
Business
🔮 holds
Hacking group claims major hack of Novo Nordisk and attempted $25 million extortion
13 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.